Myelin Oligodendrocyte Glycoprotein - MOG
MOG protein a key autoantigen
in multiple sclerosis
Myelin Oligodendrocyte Glycoprotein (MOG), a 26- to 28-kDa protein, is a member of the immunoglobulin superfamily. It is expressed exclusively in the central nervous system (CNS), specifically on the surface of myelinating oligodendrocytes and external lamellae of myelin sheath. Although MOG protein constitutes only 0.01-0.05% of the CNS myelin proteins, it is a major antigen candidate for inducing the autoimmune disease multiple sclerosis (MS). Myelin Basic Protein (MBS) and PLP (Myelin Proteolipid Protein) may play similar functions.
Monitoring autoantibodies to MBP, MOG and/or PLP is a useful tool to study the disease, its progression as well as the effect of potential inhibitors. AnaSpec (Eurogentec's US subsidiary) was pioneer in developing proprietary ELISA Assay Kits for such autoantibodies.
MOG (35-55), the most popular antigen used to induce EAE
MOG (35-55) is able to induce autoantibody production and relapsing-remitting neurological disease causing extensive plaque-like demyelination. Autoantibody response to MOG (35-55) has been observed in MS patients and MOG (35-55)-induced experimental autoimmune encephalomyelitis (EAE) C57/BL6 mice and Lewis rats.
Every lot of MOG (35-55) peptide is tested and proven to induce EAE.
Experimental Autoimmune Encephalomyelitis
A well-established animal model of MS is Experimental Autoimmune Encephalomyelitis (EAE), an inflammatory demyelinating disease of the CNS mostly induced in mice and rats. The most commonly used antigens are the MBP, MOG or PLP recombinant proteins, or peptides thereof. These antigens all lead to distinct EAE models with their own disease specificities. MBP (69-85), MOG (35-55), PLP (139-151) and PLP (178-191) have all proved efficient as EAE antigens.
References
- Linares, D. et al. Protein Expression and Purif. 34, 249 (2004)
- Bettadapura, J. et al. J. Neurochem. 70, 1593 (1998)
- Oliver, AR. et al J. Immunol. 171, 462 (2003)
- Von Budingen, H-C. et al. J. Clin. Immunol. 21, 155 (2001)
- Lyons, J-A. et.al. Eur. J. Immunol. 29, 3432 (1999)
- Von Budingen, H-C. et.al. Eur. J. Immunol. 34, 2072 (2003)
- Grima, B. et al. J. Neurochem. 59, 2318 (1992)
- Tabira, TJ. and I. Kira, Biology and Chemistry 783. CRC Press, Boca Raton (1992)
- De Rosbo, NK. et al. J. Immunol. 173, 1426 (2004).